Search results for " breast"

Effect of conditioned media from osteo- and adipodifferentiating mesenchymal stem cells on triple negative MDA-MB231 breast cancer cells

2013

Cytochemical and molecular analyses on mitochondria of immortalized and neoplastic epithelial cells of the human breast after cadmium treatments

2008

Synergistic cytotoxic interaction of the HDAC inhibitor SAHA with the natural compound parthenolide in MDA-MB231 breast cancer cells.

2013

Combined treatment of caffeic acid and DMAPT induces AMPK dependent death in MDA-MB231 cells

Relationship between Thymidylate synthase and p53 and response versus taxane adjuvant chemotherapy for breast carcinoma

2011

Many drugs can be used for adjuvant therapy of breast cancer, including anthracyclines, cyclophosphamide, 5-fluorouracil (5-fU) and, recently, taxanes (TXT) have shown promising results. 5-FU blocks thymidylate synthase (TS) which cross-links p53 mRNA, inhibiting its synthesis. TS overexpression is one of the main mechanisms involved in 5-FU drug resistance. Enough p53 mutations can confer resistance to chemotherapy using anthracyclines and 5-FU, while are associated with improved responses to TXT. The aim of this study was to examine the TS and p53 levels in tumor samples and to compare the efficacy of FEC (5-FU, epirubicin, cyclophosphamide) and TXT chemotherapy in a group of patients wit…

CD1a expression in primary breast cancer and lymph nodes: correlation with clinicopathological parameters.

2006

Presence and interaction in tissues of atrial natriuretic peptide,oxytocin and vasopressin:new insights.

2010

Atrial natriuretic peptide, oxytocin and vasopressin are three well known and widely studied molecules since many years. They have been fully characterised from a genetic and biomolecular point of view and a number of receptor-dependent functions have been recognised for them. Nevertheless, in the last years our group has conducted morphologic studies, using an immunohistochemical approach complemented by molecular biology techniques, and could show non-canonical localization and co-localization of these peptides in normal and pathologic tissues, that permitted us to postulate that they may be involved in a wider range of functions than usually assumed and not yet fully understood. In this …

CMYC PROMOTER BINDINGPROTEIN 1 (MBP1) AS A NOVEL MARKER TO IDENTIFY NEW SUBTYPES OF ERBB2 NEGATIVE BREAST TUMORS

2011

From molecular analysis to histopathology: alpha-enolase/MBP1 isoforms expression in breast cancer

2008

Identification of a prognostic gene signature associated with MBP-1 expression in ErbB2-negative breast carcinomas

2014

The ENO1 transcript, which encodes the glycolitic enzyme alpha-enolase, can be translated into a shorter nuclear protein called Myc-promoter Binding Protein-1 (MBP-1) by using an alternative translation start site. MBP-1 acts as a negative regulator of c-Myc, ErbB2 and Cox2 genes (1). Several evidences indicate that MBP-1 acts as a tumor suppressor in breast carcinoma and prostate cancer and its expression results in a reduced invasive ability (2). In our previous studies, we showed that MBP-1 is expressed and easily detectable in normal breast epithelial cells, but a loss of expression occurs in most primary invasive ductal carcinomas (IDC) of the breast. Furthermore, in these tumors MBP-1…